Dan Vergano

Dan Vergano is a senior editor at Scientific American, where he steers news coverage that ties health science to federal policy, clinical research and the ethics of powerful institutions. He brings decades of science reporting experience across outlets including Grid News, BuzzFeed News, National Geographic and USA TODAY, which gives his health stories a strong grounding in evidence, regulation and long-running scientific debates. His recent work tends to frame medical questions through rules, trials and contested diagnoses rather than lifestyle advice, making his coverage distinct from beat reporters who focus mainly on clinical practice or consumer health.

Health policy and clinical trials

Vergano’s health reporting often starts from the machinery of federal policy and its effect on research and care. In his coverage of proposed White House regulations that could terminate nearly 5,000 federally funded clinical trials, including about 1,000 cancer treatment tests, he focuses on the Office of Management and Budget rule that would give political appointees final authority over research grants instead of scientific peer review. He explains how an advocacy group’s analysis of roughly 10,000 National Institutes of Health trials suggests almost half could be at risk, turning an abstract rule change into specific numbers and consequences for patients and investigators. In a piece on a leading obstetrician group’s vaccine schedule that opposes CDC guidance, he similarly traces how professional societies interpret safety data and balance risk for pregnant patients, highlighting tensions between federal recommendations and frontline clinical judgment.

Contested conditions and medical evidence

Vergano devotes substantial attention to conditions where diagnosis, cause and even existence are debated, using Havana Syndrome as a recurring case study. He has spent years reporting on the diplomats and intelligence personnel who report symptoms, detailing how functional disorders—conditions where the brain’s “software” misfires—can arise from stress, emotional reactions or difficulty coping with events, drawing on explanations from NIH sources. His work lays out the changing epidemiological picture, noting that newer medical reports include cases dating to 2015 while earlier CDC work traced the phenomenon to 2016, and that the tally of affected individuals spans dozens to hundreds of Americans, roughly two dozen Canadians and none reported elsewhere. Across this coverage he stresses timelines, case counts and the limits of current evidence, capturing both the human anxiety around unexplained symptoms and the methodological rigor required to attribute causation. That same insistence on data and uncertainty also shapes his vaccine and clinical trial stories, where he foregrounds how different institutions read the same evidence and reach conflicting health recommendations.

Science ethics and institutional power

Many of Vergano’s health-adjacent pieces focus on who holds power in science and medicine and how that affects trust. In his reporting on a Nobel Prize–winning brain scientist stepping down over ties to Jeffrey Epstein, he examines the complex relationships between elite researchers, a disgraced financier and the broader scientific community, showing how private funding and personal networks can warp ethical boundaries. He has also written on slashed science funding, mass firings and political edicts on what researchers may study or say, describing how these pressures prompted an open letter signed by members of the National Academies of Sciences, Engineering and Medicine. Historical work on topics such as slavery in Scientific American’s archives extends this ethical lens backward, asking how a science magazine has treated a “peculiar institution” over 167 years and why revisiting that record matters for today’s discussions of race, medicine and research. Together, these stories show a consistent interest in the governance of health and science—who sets rules, who benefits, and how abuses or blind spots emerge.

Archives and the long view of science and medicine

Alongside news, Vergano frequently mines Scientific American’s 180-year archive to put modern health issues in historical context. He has contributed “50 and 100 Years Ago” and related retrospective pieces that revisit past coverage on topics ranging from weight loss interventions to public health on cruise ships, using old stories and images to show how medical thinking and policy have evolved. He has written about the magazine’s treatment of slavery and other social questions, blending archival work with current ethical debates in science. Earlier in his career, his reporting at USA TODAY included coverage of a study suggesting St. John’s wort might weaken birth control, as well as a 4.4-million-year-old fossil that could reshape views of human origins, reflecting a longstanding interest in how scientific evidence upends assumptions about bodies and evolution. He has also profiled figures such as David Attenborough on milestones like a 100th birthday, connecting biology, media and public understanding of the natural world. Across these historical and feature pieces, Vergano’s hallmark is using time—decades of archives, long-running debates and career-spanning examples—to situate contemporary health controversies within a larger narrative of how science, medicine and society change.

In his current editorial role, Vergano combines this investigative, archival and ethical perspective with a focus on health policy, clinical research and contested conditions. He is as likely to examine a rule that could halt thousands of trials or a rift between an obstetric society and the CDC as he is to dissect the evidence behind a mysterious syndrome, always centering institutions, data and history over quick-take medical advice.